Drug Coated Balloons for Prevention of Restenosis (Piccolo)

Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons

The study will be performed as a randomized, double blind trial (in respect of the primary end point) with treatment of the stenotic lesion using uncoated PTA-catheters as control group. 114 patients will be included in the trial at about 5 study centers. Follow-up includes control angiography after 6 and 18 months and clinical follow-up examinations up to 18 months. Primary objective:

Efficacy of paclitaxel coated PTA balloons in inhibiting restenosis of below the knee arteries (late lumen loss)

Secondary objective:

Various angiographic and clinical efficacy measures, safety and tolerance of pacli-taxel coated PTA balloons in inhibiting restenosis of below the knee arteries Descriptive statistics, comparison by t-test, chi-square test for binary events 10.1 Descriptive statistics As far as applicable descriptive statistics will be applied to data and will be referring to individual changes versus baseline (predilatation or immediately postdilatation). The groups will be compared to each other testing the statistical significance of differences (p ≤ 0.05). Con-tinuous data will be expressed as mean ± standard deviation.

Categorical variables will be compared using the chi-squared test, and continuous variables will be compared using Student's t test or ANOVA analysis.

In addition to the assessment of the primary endpoint and the secondary endpoints a multi-variate analysis to investigate the influence of risk factors on the interventional outcome (interventional success, early restenosis/occlusion, LLL, stent integrity) and clinical outcomes will be performed. For this analysis the following factors will be considered: age, diabetes, neurological status (only Rutherford 5), lesion length, grade of dissection and calcification, reststenosis, number of run-off vessels, stent administration in the index lesion(s).

10.2 Estimated number of patients The primary endpoint of the study is late lumen loss (LLL) at 6 months evaluated by quantitative angiography. Because no data according this endpoint are available for both the control group and the group which will be treated with the paclitaxel coated balloon an assumption according the LLL at 6 months was made according the expectations of the principle investigator. An estimate for LLL as % of MLD in the control group is 50% and in the drug coated balloon group 30 %. The standard deviation is calculated to be 30% of LLL. A sample size of 37 patients in each group will allow the detection of a statistically significant difference (p<0.05) with 80% power. Based on the "Below study" which enrolled patients with comparable arterial lesions in Tuebingen and the data of the Basil study, it is estimated that 35% of the patients who will be enrolled in the study will not be available for follow-up investigations in order to calculate the MLD.

In order to meet a statistical endpoint a total of 114 patients will be enrolled.

Study Overview

• Status: Unknown
• Conditions: Atherosclerosis; Restenosis; Limb Ishemia
• Intervention / Treatment: Device: Balloon angioplasty (uncoated conventional balloon); Device: Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)

• Study Type: Interventional
• Enrollment (Anticipated): 114
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Germany
  • B
    • Berlin, B, Germany, 10001
      • Active, not recruiting
      • Charité Berlin
    • Berlin, B, Germany, 10001
      • Active, not recruiting
      • Jüdisches Krankenhaus Berlin
  • BW
    • Bad Krozingen, BW, Germany, 76551
      • Recruiting
      • Herzzentrum Bad Krozingen
      • Contact: Thomas Zeller, MD; Email: thomas.zeller@herzzentrum.de
    • Tuebingen, BW, Germany, 72076
      • Recruiting
      • University of Tuebingen
      • Contact: Gunnar Tepe, MD; Phone Number: 83371 49-707-129; Email: gunnar.tepe@med.uni-tuebingen.de
  • MP
    • Rostock, MP, Germany, 01065
      • Active, not recruiting
      • University of Rostock

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 95 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age between 18 and 95 years,
• peripheral vascular disease, Rutherford stage 3-5, diameter stenosis ≥ 70 %, ≥ 15 -150 mm length, up to 2 vessels to be treated

Exclusion Criteria:

• Disease associated with life-expectancy less than 18 months
• Acute thrombus or aneurysm in the index limb/ vessel
• Doubts in the willingness or capability of the patient to allow follow up examination

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: A; Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)	Device: Balloon angioplasty (uncoated conventional balloon); endovascular therapy
Active Comparator: 2; Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)	Device: Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel); endovascular therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Primary endpoint: Late lumen loss (LLL) of the target lesion after 6 months (assessed by DSA)	after 6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Interventional success rate (defined as reststenosis less than 50%)	up to 18 months
Restenosis rate at 6 and 18 months (restenosis rate is defined as a diameter stenosis of ≥ 50% of reference diameter	up to 18 months
Minimum lumen diameter (MLD) at 6 months	up to 18 months
Target lesion revascularization recorded at 6, 12 and 18 months; target lesion revascularization is defined as any reintervention or artery bypass graft surgery involving the target lesion.	up to 18 months
Target vessel revascularization recorded at 6, 12 and 18 months	up to 18 months
Target limb revascularization recorded at 6, 12 and 18 months	up to 18 months
Improvement of clinical stage at 6, 12 and 18 months	up to 18 months
Change in ABI compared to pretreatment if vessels are compressible	up to 18 months
Hospitalization (extra days due to complications of the index procedure) and hospitalization between the follow-up visits due to the index leg	up to 18 months
Major amputations at the index limb	up to 18 months
Mortality	up to 18 months
LLL of stented segments at 6 months comparing the uncoated and the coated bal-loon group.	up to 18 months
Subgroup analysis; primary endpoint and TLR	up to 18 months
LLL, MLD and restenosis rate at 18 month follow-up determined by angiography	up to 18 months
Subgroup analysis neuropathy and no neuropathy according to clinical improve-ment in patients classified Rutherford 5	up to 18 months
Clinical benefit patients Rutherford 3 vs. Rutherford 4 and 5	up to 18 months

Collaborators and Investigators

• Sponsor: University Hospital Tuebingen

Publications and helpful links

General Publications

• Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.

Study record dates

Study Major Dates

• Study Start: April 1, 2008
• Primary Completion (Anticipated): April 1, 2011
• Study Completion (Anticipated): April 1, 2011

Study Registration Dates

• First Submitted: June 10, 2008
• First Submitted That Met QC Criteria: June 12, 2008
• First Posted (Estimate): June 13, 2008

Study Record Updates

• Last Update Posted (Estimate): June 13, 2008
• Last Update Submitted That Met QC Criteria: June 12, 2008
• Last Verified: May 1, 2008

More Information

Terms related to this study

• Keywords: balloon angioplasty; local drug delivery; safety and tolerance of paclitaxel coated PTA balloons; in inhibiting restenosis of below the knee arteries; Efficacy of paclitaxel coated PTA balloons; in inhibiting restenosis of below the knee arteries (late lumen loss)
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: Pac-3